A Study of Acupuncture for Treating Asthma
28. maj 2026 opdateret af: Lei-Miao Yin, Shanghai University of Traditional Chinese Medicine
The Effects of Acupuncture on Patients With Chronic Asthma: a Multicenter, Randomized, Three-arm, Sham-controlled Superiority Trial
Asthma is a common chronic respiratory disease with a low clinical control rate, highlighting the need for novel therapeutic strategies.
Recurrent asthma attacks emotional symptoms, such as anxiety and depression, etc.
On the contrary, symptoms such as anxiety and depression worsen asthma control.
Acupuncture is commonly applied as an effective traditional Chinese medical therapy for asthma.
Acupoints GV14, BL13 and BL12 are adopted for the intervention of asthma.
GV20 and GV29 are selected to improve emotional symptoms including depression.
Nevertheless, standardized therapeutic regimens of acupuncture for asthma and its concomitant emotional symptoms are still lacking.
180 patients with mild to moderate asthma will be recruited in this multicenter randomized controlled trial, randomly assigned to the true acupuncture group, sham acupuncture group and usual care group.
The primary outcome is the score of the Asthma Control Test (ACT).
Secondary outcomes include the Hospital Anxiety and Depression Scale (HADS), Asthma Quality of Life Questionnaire (AQLQ), pulmonary function, and fractional exhaled nitric oxide (FeNO).
The superiority of combined acupuncture therapy in improving asthma control, relieving negative emotions, and enhancing quality of life is to be verified in this study, with high quality evidence for acupuncture treatment of asthma thereby to be provided.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
180
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Lei-Miao Yin, MD
- Telefonnummer: +86 21 56639828
- E-mail: collegeylm@shutcm.edu.cn
Undersøgelse Kontakt Backup
- Navn: Xin Luan, MD
- Telefonnummer: +86 17701614380
- E-mail: lx931163088@163.com
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Meet the diagnostic criteria for asthma, and be in the chronic persistent phase with mild to moderate disease severity, referring to the grading criteria of the Guidelines for the Prevention and Treatment of Asthma (2024 Edition).
- Aged 18 to 70 years, regardless of gender.
- Asthma Control Test (ACT) score≤19 points (poorly controlled or very poorly controlled asthma).
- Maintain a stable asthma treatment regimen for at least 4 weeks before enrollment.
- Clear thinking and consciousness, coherent responses, able to understand the items of various scales and complete the assessment.
- Volunteer to participate in this study and sign a written informed consent form.
Exclusion Criteria:
- Complicated with severe mental illnesses (such as uncontrolled schizophrenia, acute phase of bipolar disorder, etc.) or moderate to severe cognitive impairment (such as dementia), resulting in inability to understand the research process or cooperate with efficacy evaluation.
- A history of substance/alcohol dependence within the past 12 months.
- Complicated with other physical diseases that may cause depressive symptoms (such as hypothyroidism, chronic pain syndrome, malignant tumors, rheumatoid arthritis, etc.).
- Received antidepressant drug treatment within the past 6 months.
- Suffering from other respiratory diseases, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, etc.
- Complicated with other cancers or relatively severe chronic diseases of the heart, liver, kidneys, etc.
- Received acupuncture treatment within the past 3 months.
- Pregnant or lactating women.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: True Acupuncture Group
Acupuncture Group: On routine standard asthma treatment, participants receive acupuncture.
Disposable sterile needles (Wuxi Jiajian Medical Instrument Co., Ltd.) are used: 0.25 mm×25 mm for Baihui (GV20), Yintang (GV29); 0.30 mm×40 mm for Dazhui (GV14), bilateral Fengmen (BL12) and Feishu (BL13).Qualified acupuncturists perform treatment following GB/T 12346-2021.
Patients sit with routine skin disinfection.
Baihui: 15-30° oblique insertion, 0.5 cun.
Yintang: downward oblique puncture 0.3-0.5 cun with skin pinched.
Dazhui: perpendicular 0.5-1 cun.
Fengmen and Feishu: perpendicular toward spine, 0.5-0.8
cun.
Even reinforcing-reducing manipulation is applied.
Each session lasts 30 minutes, 3 times weekly for 10 sessions.
Eye masks are used; operators are separated from outcome assessors.
|
Patients are seated with routine disinfection of acupoints.
Dazhui (GV14) is perpendicularly needled 0.5-1 cun; Feishu (BL13) and Fengmen (BL12) are perpendicularly needled toward the spine for 0.5-0.8
cun; Baihui (GV20) is needled subcutaneously at 15-30° to the scalp for 0.5 cun; Yintang (GV29) is obliquely needled downward for 0.3-0.5 cun after pinching local skin .
Even reinforcing-reducing manipulation is adopted.
Each treatment lasts 30 minutes, three times weekly (no treatment on Sundays) for 10 consecutive sessions.
Eye masks are used, with separation of operators and outcome assessors.
|
|
Sham-komparator: Sham Acupuncture Group
Sham Acupuncture Group: On the basis of routine standard asthma treatment, participants receive Streitberger placebo needle intervention.
The Streitberger placebo needle (Asiamed GmbH, Germany) is a non-penetrating sham acupuncture device with identical appearance to real needles but a blunt tip.
Upon gentle skin contact, the shaft retracts into the handle, secured by an external patch to simulate needle insertion visually.
The same acupoints are used as in the acupuncture group: GV14, BL13, BL12, GV20 and GV29.Participants sit with routine skin disinfection.
The placebo needle base pad is fixed on acupoints.
Vertical pressure on the handle retracts the shaft without skin penetration.
Each session lasts 30 minutes, 3 times weekly for 10 consecutive sessions.
Needles are removed directly without hemostasis.
Eye masks are used during treatment; operators are separated from outcome assessors.
|
Patients are seated with routine disinfection of acupoints.
Streitberger non-penetrating placebo needles are applied to the same acupoints as true acupuncture (Dazhui GV14, Feishu BL13, Fengmen BL12, Baihui GV20, Yintang GV29) with identical position, duration and frequency.
Each sham session lasts 30 minutes, three times weekly (no treatment on Sundays) for 10 consecutive sessions.
Eye masks are used, with separation of operators and outcome assessors.
|
|
Aktiv komparator: Usual Care Group
Participants receive only standard pharmacological treatment for asthma in accordance with clinical guidelines, without any acupuncture or related interventions.
|
Patients receive routine asthma pharmacological treatment without additional acupuncture intervention.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Asthma Control Test (ACT)
Tidsramme: Change from baseline to week 4 (end of treatment)
|
The Asthma Control Test (ACT) is a validated 5-item self-reported questionnaire assessing overall asthma control, with total scores ranging from 5 to 25.
Higher scores indicate better asthma control.
|
Change from baseline to week 4 (end of treatment)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hospital Anxiety and Depression Scale (HADS)
Tidsramme: Change from baseline to week 4 (end of treatment)
|
A validated self-rating scale containing anxiety (HADS-A) and depression (HADS-D) subscales, each with 7 items.
Lower scores indicate less anxiety and depressive symptoms.
|
Change from baseline to week 4 (end of treatment)
|
|
Asthma-Specific Quality of Life Questionnaire (AQLQ)
Tidsramme: Change from baseline to week 4 (end of treatment)
|
A validated self-reported questionnaire evaluating asthma-related quality of life, covering symptoms, activity limitation, emotional function and environmental stimuli.
Higher scores represent better quality of life.
|
Change from baseline to week 4 (end of treatment)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Efterforskere
- Studieleder: Lei-Miao Yin, MD, Shanghai Municipal Hospital of Traditional Chinese Medicine
- Studiestol: Ping Yin, MD, Longhua Hospital
- Studiestol: Xin-Yun Huang, MD, Yueyang Hospital, Shanghai University of Traditional Chinese medicine
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
21. maj 2026
Primær færdiggørelse (Anslået)
1. marts 2028
Studieafslutning (Anslået)
1. september 2028
Datoer for studieregistrering
Først indsendt
21. maj 2026
Først indsendt, der opfyldte QC-kriterier
21. maj 2026
Først opslået (Faktiske)
28. maj 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
1. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
28. maj 2026
Sidst verificeret
1. maj 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Sygdomme i immunsystemet
- Luftvejssygdomme
- Lungesygdomme
- Bronchiale sygdomme
- Lungesygdomme, obstruktiv
- Respiratorisk overfølsomhed
- Overfølsomhed, Øjeblikkelig
- Overfølsomhed
- Patologiske tilstande, tegn og symptomer
- Astma
- Sygdom
- Terapeutik
- Komplementære terapier
- Akupunkturbehandling
Andre undersøgelses-id-numre
- 2026SHL-KY-68-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
Individual participant data will not be shared due to participant privacy protection and limited research resources
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .